A groundbreaking leap in precision oncology has arrived. Shine-On Biomedical Co., in collaboration with China Medical University Hospital (Taiwan), has developed the world's first
HLA-G targeted exosome drug delivery platform—SOB100. Built on nanobody (VHH) technology, SOB100 has now entered U.S. clinical trials following FDA approval on March 8, 2025.

What Is SOB100?

SOB100 is a first-in-class therapeutic platform that uses gene-engineered exosomes to precisely target HLA-G, a molecule exploited by cancer cells to suppress immune detection. While normally found in placental tissue, HLA-G is overexpressed in many aggressive cancers such as glioblastoma and triple-negative breast cancer (TNBC).

Engineered with nanobodies embedded in the exosome membrane, SOB100 binds specifically to HLA-G, delivering small molecule or nucleic acid drugs directly to tumor cells. This minimizes off-target effects and enhances therapeutic precision—especially across challenging barriers like the blood-brain barrier.

Why HLA-G Matters in Cancer Therapy

HLA-G helps tumor cells evade immune detection, a major contributor to treatment resistance. By targeting this molecule, SOB100 not only delivers drugs more precisely but also helps counteract the immune-suppressive environment created by tumors.

This makes SOB100 uniquely positioned to address unmet needs in treating high-grade, drug-resistant cancers.

Backed by Recognition and Global Collaboration

Shine-On Biomedical has been recognized by Clarivate as one of the top 10 global developers in exosome therapeutics. SOB100 has received multiple awards, including:

• National Innovation Award (Taiwan)

• International Innovation Award (Taiwan)

• Merck Emerging Biotech Special Award (U.S.)

The company has also partnered with a Singapore-based exosome manufacturer to co-develop SOB100-based therapies and expand into international markets.

A New Hope for Precision Oncology

SOB100 represents a new generation of cancer therapies:

• Non-viral, scalable, and low-toxicity drug delivery

• Highly specific tumor targeting

• Effective against resistant cancers like glioblastoma
  

As the platform enters human trials in the U.S., it stands to redefine how we approach cancer treatment—with nanobody precision and exosome innovation leading the way.

Source: WVNews